Logo
IMMUNOTHERAPY DRUGS MARKET ANALYSIS
  2. / Market Insights
  3. Immunotherapy Drugs Market Analysis
all report title image

IMMUNOTHERAPY DRUGS MARKET ANALYSIS

Immunotherapy Drugs Market, By Therapy Type (Immune checkpoint inhibitors, Monoclonal antibodies, Vaccines, Adoptive Cell Therapies, Immune System Modulators, Oncolytic Virus Therapy), By Route of Administration (Intravenous, Oral, Intramuscular, Subcutaneous, Others), By Indication (Cancer, Autoimmune Diseases, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Apr 2024
  • Code : CMI525
  • Pages :150
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Market Concentration and Competitive Landscape

Immunotherapy Drugs Market Concentration By Players

Close-monitor your Competitor's Move, Get Instant Access to the Report

Key Players Insights
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Fate Therapeutics.
  • Gritstone bio
  • Incyte
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • BioNTech SE
  • Cellectis

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Press Release

Immunotherapy Drugs Market is estimated to be valued at USD 166.55 Billion in 2024
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.